British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine
The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac.
The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it.
More Stories
Europe will never return to Russian gas, European Commission insists
Majority of Australians think China will be world’s most powerful country by 2035, poll finds
Oil and gold prices soar and stock markets fall after Israel’s attacks on Iran